Literature DB >> 19843060

In vitro and in vivo evaluation of the inhibition potential of risperidone toward clozapine biotransformation.

Manoranjenni Chetty1, Fabrizio d'Esposito, Wei V Zhang, John Glen, Glenys Dore, Zvijezdana Stankovic, Robert J Edwards, Iqbal Ramzan, Michael Murray.   

Abstract

AIMS: To study the impact of risperidone (RISP) on clozapine (CLZ) biotransformation in vitro in microsomal fractions containing varying expression of CYP oxidases and in vivo in patients.
METHODS: Human liver microsomes (n= 11) were assessed for expression of CYPs 1A2, 2D6 and 3A4, because these enzymes mediate RISP and CLZ oxidation. Inhibition of CLZ oxidation by RISP was assessed. Plasma CLZ elimination was estimated in patients with schizophrenia who received either CLZ alone or the CLZ-RISP combination (n= 10 per group).
RESULTS: (i) The CYP3A4 and CYP1A2 inhibitors ketoconazole and fluvoxamine inhibited CLZ oxidation to varying extents in individual microsomal fractions. (ii) RISP did not inhibit CLZ oxidation, regardless of variations in CYP expression. (iii) RISP co-administration did not impair CLZ clearance.
CONCLUSIONS: No evidence was found for CYP-mediated inhibitory or pharmacokinetic interactions between RISP and CLZ. Occasional literature reports of such interactions may involve other pathways that participate in CLZ disposition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843060      PMCID: PMC2780282          DOI: 10.1111/j.1365-2125.2009.03476.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline.

Authors:  M Murray
Journal:  Mol Pharmacol       Date:  1992-11       Impact factor: 4.436

2.  A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

Authors:  J A Bork; T Rogers; P J Wedlund; J de Leon
Journal:  J Clin Psychiatry       Date:  1999-07       Impact factor: 4.384

3.  The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography.

Authors:  M J Lovdahl; P J Perry; D D Miller
Journal:  Ther Drug Monit       Date:  1991-01       Impact factor: 3.681

4.  Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.

Authors:  R Nesvåg; M Hendset; H Refsum; L Tanum
Journal:  Acta Psychiatr Scand       Date:  2006-07       Impact factor: 6.392

5.  Direct fluorometric methods for measuring mixed function oxidase activity.

Authors:  R A Prough; M D Burke; R T Mayer
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

6.  The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.

Authors:  B Eiermann; G Engel; I Johansson; U M Zanger; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1997-11       Impact factor: 4.335

7.  Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.

Authors:  Richard C Josiassen; Ashok Joseph; Eva Kohegyi; Sudhir Stokes; Mahmood Dadvand; Wynn Wynn Paing; Rita A Shaughnessy
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

8.  Metabolism and bioactivation of clozapine by human liver in vitro.

Authors:  M Pirmohamed; D Williams; S Madden; E Templeton; B K Park
Journal:  J Pharmacol Exp Ther       Date:  1995-03       Impact factor: 4.030

9.  Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans.

Authors:  R J Edwards; D A Adams; P S Watts; D S Davies; A R Boobis
Journal:  Biochem Pharmacol       Date:  1998-08-01       Impact factor: 5.858

10.  Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.

Authors:  D C Henderson; D C Goff
Journal:  J Clin Psychiatry       Date:  1996-09       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.